infectious laryngotracheitis virus 10386 Baboon Papio cynocephalus 9556 Bank vole Clethrionomys glareolus 447135 Bear Ursus americanus 9643 Birds Passeroidea 175121 Brown Trout Salmo trutta 8032 Buffalo Bison bison 9901 Carnivores Vulpes 9625 Cat Felis catus 9685 Catfishes Siluriformes 7995 Cattle Bos taurus 9913 Chicken Gallus gallus 9031 Chimpanzee Pan troglodytes 9598 chinchillas Chinchillidae 10150 Copper Pheasant Syrmaticus soemmerringii 9067 Deer Cervus elaphus 9860 Deer mouse Peromyscus maniculatus 10042 Dog Canis familiaris 9615 Ducks Anas 8835 Ferret Mustela putorius furo 9669 Fish Hyperotreti 117565 Gerbil Gerbillina 10045 Goat Capra hircus 9925 Gray wolf Canis lupus 9612 Guinea pig Cavia porcellus 10141 Hamster Mesocricetus auratus 10036 Horse Equus caballus 9796 Human Homo sapiens 9606 Macaque Macaca fascicularis 9541 Mongolian Gerbil Meriones unguiculatus 10047 Monkey Platyrrhini 9479 Mouse Mus musculus 10090 None None Parrot Psittacidae 9224 Pig Sus scrofa 9823 Rabbit Oryctolagus cuniculus 9986 Rainbow trout Oncorhynchus mykiss 8022 Rat Rattus 10114 Raven Corvus corax 56781 sei whale Balaenoptera borealis 9768 Sheep Ovis aries 9940 Squirrel Spermophilus richardsonii 37591 Tree shrew Tupaiidae 9393 Trouts, salmons & chars Salmoninae 504568 Turkey Meleagris gallopavo 9103 Vole Microtus ochrogaster 79684 Water buffalo Bubalus bubalis 391902 FPV-LT vaccine VO_0004624 Recombinant vector vaccine Research Intramuscular injection (i.m.) Viral vector vaccines using fowl poxvirus (FPV) and herpesvirus of turkey (HVT) as vectors and carrying infectious laryngotracheitis virus (ILTV) genes (Vagnozzi et al., 2012). Intramuscular injection (i.m.) Live-attenuated ILT vaccines were administered as a full dose, and the recombinant vectored vaccines were administered as a half dose to mimic broiler industry practices. The viral vector vaccines were administered in ovo and subcutaneously at hatch while the live-attenuated vaccines, CEO and TCO, were administered via eye drop at 14 days of age (Vagnozzi et al., 2012). VO_0003057 The FPV-LT vaccine mitigated clinical signs more effectively when administered subcutaneously than in ovo (Vagnozzi et al., 2012). All chickens were weighed before challenge. With the exception of the NVx-NCh group, all chickens were challenged at 35 days of age with the virulent ILTV field isolate 63140 administered in a total volume of 200 µl, 100 µl intratracheally and 50 µl via eye drop per eye (Vagnozzi et al., 2012). HVT-ILT(FC-126 strain) VO_0004756 Recombinant vector vaccine Research Intramuscular injection (i.m.) Turkey herpesvirus vector laryngotracheitis vaccine (HVT/LT) expressing the glycoprotein B gene of laryngotracheitis virus (LTV) (Esaki et al., 2013). Intramuscular injection (i.m.) The chickens were vaccinated with HVT/LT by the subcutaneous route at 1 day of age (Esaki et al., 2013). VO_0000287 The majority of the vaccinated chickens (92%-100%) were protected against challenge with virulent LTV. Efficacy of HVT/LT was further evaluated in broiler chickens from a commercial source after in ovo vaccination to embryos at 18 days of incubation. After challenge with virulent LTV at 21 and 35 days of age, 67% and 87% of HVT/LT-vaccinated chickens did not develop LT clinical signs, respectively, while 100% (21 days of age) and 73% (35 days of age) of the challenge control chickens showed clinical signs of LT (Esaki et al., 2013). The vaccinated chickens were challenged with virulent LTV at 7 weeks of age (Esaki et al., 2013). HVT-LT VO_0004793 Recombinant vector vaccine Research Intramuscular injection (i.m.) Viral vector vaccines using fowl poxvirus (FPV) and herpesvirus of turkey (HVT) as vectors and carrying infectious laryngotracheitis virus (ILTV) genes (Vagnozzi et al., 2012). Intramuscular injection (i.m.) Live-attenuated ILT vaccines were administered as a full dose, and the recombinant vectored vaccines were administered as a half dose to mimic broiler industry practices. The viral vector vaccines were administered in ovo and subcutaneously at hatch while the live-attenuated vaccines, CEO and TCO, were administered via eye drop at 14 days of age (Vagnozzi et al., 2012). VO_0000287 The chicken embryo origin vaccine provided optimal protection by significantly mitigating the disease and reducing the challenge virus in chickens vaccinated via eye drop. The viral vector vaccines, applied in ovo and subcutaneously, provided partial protection, reducing to some degree clinical signs, and challenge VIRUS replication in the trachea (Vagnozzi et al., 2012). All chickens were weighed before challenge. With the exception of the NVx-NCh group, all chickens were challenged at 35 days of age with the virulent ILTV field isolate 63140 administered in a total volume of 200 µl, 100 µl intratracheally and 50 µl via eye drop per eye (Vagnozzi et al., 2012). Innovax-ILT Merck Animal Health Recombinant vector vaccine Licensed Herpesvirus of turkeys as the vector [Ref5975:Loncoman et al., 2018] Intramuscular injection (i.m.) Europe Innovax-ILT is a recombinant vector vaccine which uses herpesvirus of turkeys as a vector (Loncoman et al., 2018) The vaccine was titrated in a secondary chicken embryo fibroblast (CEF) monolayer in 60 mm plates. Ten-fold dilutions of the reconstituted vaccine were produced in Dulbecco’s modified Eagle medium (DMEM), and 200 μL of each dilution was added to three plate replicates. The inoculated cells were incubated at 37 °C and 5% CO2 for 5 days. At day 5 following inoculation, plaques were microscopically counted. Virus titer was calculated and recorded as 6360 plaque forming units (PFU)/per dose. (Loncoman et al., 2018) Intramuscular injection (i.m.) rFPV-ILTV VO_0004744 Recombinant vector vaccine Research Intramuscular injection (i.m.) ILTV viral vector recombinant vaccines (Johnson et al., 2010). Intramuscular injection (i.m.) VO_0000287 Both recombinant-vectored ILTV vaccines provided partial protection, thereby mitigating the disease, but did not reduce challenge virus loads in the trachea (Johnson et al., 2010). rNDV-ILTV-gD VO_0004680 Recombinant vector vaccine Research Intramuscular injection (i.m.) Intramuscular injection (i.m.) VO_0003057 rNDV gD showed complete protection against virulent ILTV challenge (Kanabagatte et al., 2014). Esaki et al., 2013 journal Esaki M, Noland L, Eddins T, Godoy A, Saeki S, Saitoh S, Yasuda A, Dorsey KM 2013 57 2 192-198 Avian diseases Johnson et al., 2010 journal Johnson DI, Vagnozzi A, Dorea F, Riblet SM, Mundt A, Zavala G, García M 2010 54 4 1251-1259 Avian diseases Kanabagatte et al., 2014 journal Kanabagatte Basavarajappa M, Kumar S, Khattar SK, Gebreluul GT, Paldurai A, Samal SK 2014 32 28 3555-3563 Vaccine Vagnozzi et al., 2012 journal Vagnozzi A, Zavala G, Riblet SM, Mundt A, García M 2012 41 1 21-31 Avian pathology : journal of the W.V.P.A Zhao et al., 2014 journal Zhao W, Spatz S, Zhang Z, Wen G, Garcia M, Zsak L, Yu Q 2014 88 15 8397-8406 Journal of virology